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ABSTRACT: whether and how IRBs assess 
social risks remains unclear, with little empirical inves-
tigation. I contacted leaders of 60 IRBs, and inter-
viewed IRB leaders from 34 (response rate = 55%) and 
additionally, 12 members and administrators. IRBs 
struggle to assess and balance social risks and benefits, 
and vary in whether, how, and how much to do so, and 
how to balance these against individual risks/benefits. 
Risks to a group affect individuals within it. Hence, 
social risks can include indirect individual risks, rais-
ing ambiguities. Dilemmas emerge: e.g., how much 
responsibility researchers and IRBs have for addressing 
broader health inequities. These data, the first to 
examine how IRBs make decisions about social risks, 
reveal how IRBs face critical challenges, dilemmas, and 
ambiguities.
KEY WORDS: ANPRM, justice, stigma, autonomy, 
vulnerability, autonomy, research ethics, equipoise
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Many questions arise that have not been examined empirically concerning whether IRBs assess and weigh consider-
ations beyond those pertaining to individual risks and 
benefits—specifically, social risks—and if so, how. The 
U.S. Code of Federal Regulations (45 CFR 46 [U.S. 
Department of Health and Human Services (HHS)], 
2005) stipulates that:
The IRB should not consider possible long-range 
effects of applying knowledge gained in the research 
(for example, the possible effects of the research on 
public policy) as among those research risks that fall 
within the purview of its responsibility.
Yet the Advanced Notice of Proposed Rule Making 
(ANPRM), released by the Department of Health and 
Human Services in July 2011 to revamp IRB regulations, 
raised questions about this statement. The ANPRM asked:
Do IRBs correctly interpret this provision as mean-
ing that . . . it is not part of their mandate to evalu-
ate policy issues such as how groups of persons or 
institutions, for example, might object to conduct-
ing a study because the possible results of the study 
might be disagreeable to them? If that is not how 
the provision is typically interpreted, is there a need 
to clarify its meaning? (HHS, 2011)
Broad questions thus arise concerning whether IRBs 
consider and weigh social risks, and if so, how, when, 
and to what extent.
These issues are important since IRBs have been 
shown to vary widely, due to a range of factors, in their 
reviews of protocols in multi-site studies, impeding the 
comparability and analysis of the data, and thus ham-
pering scientific progress (Shah et al., 2004; Dziak et al., 
2005). Previous articles have suggested that IRBs vary 
widely in how they interpret and apply regulations and 
guidelines concerning consent forms (Klitzman, 2013a) 
and conflicts of interest (Klitzman, 2013b), and are 
shaped by various factors, including the local ecologies 
in which they work (Klitzman, 2012a). Hence, under-
standing how they interpret and apply federal regula-
tions is vital. In addition, American bioethics has been 
criticized more generally for focusing too much on the 
individual, rather than on broader social issues (Fox & 
Swayze, 2008). 
Yet strikingly, no empirical studies appear to have been 
conducted examining these issues of how they view, and 
make decisions about, potential social harms. Fleischman 
et al. (2011) argued that in four realms—behavioral 
genetics, adolescent behavior, harm reduction, and 
human genetic enhancement—local IRBs do at times 
consider social risks, though 45 CFR 46 (as quoted 
above) instructs these committees not to do so. IRB con-
sideration of the social implications of research proto-
cols, these authors conclude, “sometimes create 
significant delays in initiating or even prevent such 
research” (Fleischman et al., 2011). These scholars 
oppose IRBs’ considerations of these issues—since “pre-
dicting negative effects of new knowledge on popula-
tions or social policy is highly speculative and essentially 
political” (ibid.). Instead, Fleischman et al. (2011) sug-
gest that national review bodies, rather than local IRBs, 
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would be best to address these issues. Yet as Melo-Martín 
(2011) points out, these authors do not provide details 
or data concerning what would be involved in having 
such national committees perform this task; and these 
committees may not be able to resolve the dilemmas that 
arise better than do IRBs. 
Given the lack of empirical data concerning these 
issues, crucial questions remain regarding how IRBs 
themselves actually view and make decisions about 
social risks, whether they differ in doing so, and if so, 
how and why. Moreover, IRBs may face these issues con-
cerning not only the four specific realms discussed by 
Fleischman et al. (2011), but more broadly in reviewing 
other types of studies.  
In general, individuals may perceive various types of 
risks and benefits differently, based on a range of factors, 
including education and past experiences (Tversky & 
Kahneman, 1981; Redelmeier, Rozin, & Kahneman, 1993; 
Kong et al., 1986; Bergus, Levin, & Elstein, 2002; Klitzman, 
2006; Klitzman, 2011a). Perceptions of risk and danger 
may involve subjective elements, related to cultural and 
individual fears, with individuals often seeking to draw 
boundaries between risk and safety that may not be wholly 
evidence-based (Douglas, 1966). But how IRB chairs, 
members, and staff perceive social risks, and balance these 
against other risks and benefits, remains unclear.
Recently, I conducted in-depth qualitative interviews 
with IRB chairs, administrators, and members about a 
series of issues, as part of which, themes arose concern-
ing how to assess and weigh social risks. The interviews 
explored how IRBs viewed and made decisions about 
research integrity (RI), broadly defined, which proved 
to be related to their views and approaches concerning 
a wide variety of other areas, including the ways they 
interpreted federal regulations (Klitzman, 2013b). 
Since the study used qualitative methods, it permitted 
in-depth exploration of these domains—including how 
IRBs perceive considerations beyond social risks, which 
the present paper thus examines.
Methods
In brief, as described elsewhere (Klitzman, 2011a–e, 
2012a–c, 2013a–b), in-depth telephone interviews of 
two hours each were conducted with 46 chairs, direc-
tors, administrators, and members. I contacted the 
leadership of 60 IRBs (every fourth one in the list of the 
top 240 institutions by NIH funding), and interviewed 
IRB leaders from 34 of these institutions, yielding a 
response rate of 55%. In certain cases, both a chair/
director as well as an administrator from an institution 
were included (e.g., if the former thought that the latter 
could better provide detail about certain areas). Thus, 
in all, I interviewed 39 chairs/directors and administra-
tors from these 34 institutions. To understand the 
impact of varying social and institutional milieus in 
these domains, I included a range of institutions in 
terms of location, size, and public/private status. I also 
asked every other one interviewed on the list by amount 
of NIH funding to disseminate information about the 
study to their IRB members, to recruit one member 
from each IRB, and thus included seven other mem-
bers, too. As summarized in Table 1, the 46 interview-
ees included 28 chairs/co-chairs; 10 administrators; one 
director; and seven members. In all, 58.7% were male, 
and 93.5% were Caucasian. Interviewees were distrib-
uted across geographic regions, and institutions by 
ranking inNIH funding.
The study was approved by the Columbia University 
Department of Psychiatry Institutional Review Board. 
All interviewees gave informed consent. The interviews 
focused on participants’ views of RI and factors involved 
in decisions, but shed important light as well on many 
other, broader issues that arose concerning IRBs’ deci-
sions, interactions, and relationships. Appendix A pres-
ents relevant portions of the semi-structured interview 
guide. I sought to obtain a “thick description”—to under-
stand aspects of their decisions, lives, and social situa-
tions by trying to grasp individuals’ own experiences and 
Table 1: Characteristics of the Sample of IRB Chairs, Mem-
bers, and Administrators
Total % (N=46)






















Total # of Institutions Represented 34
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language, not by imposing theoretical structures (Geertz, 
1973). Interviewees discussed a broad range of types of 
studies that they had reviewed. 
I adapted elements from grounded theory (Strauss & 
Corbin, 1990), engaging in techniques of “constant com-
parison,” analyzing data from different contexts for simi-
larities and differences. During the period when I was 
conducting the interviews, interviews were transcribed 
and underwent initial analysis to enhance validity. 
After completion of all of the interviews, a trained 
research assistant (RA) and I conducted additional analy-
ses in two phases. In the first phase, we analyzed a subset 
of interviews independently to gauge factors that affected 
interviewees’ experiences, identifying sets of recurrent 
issues and themes to which we then gave codes (e.g., dis-
cussions about social risks). Together, we then reconciled 
these independently developed coding schemes into a 
coding manual, listing and defining the codes.
In the second phase of the study, we independently 
content-analyzed the interviews, examining the main sub-
categories, and ranges of variation in each of the core cat-
egories. We reconciled the subthemes each coder noted 
into a single set of “secondary” themes and an elaborated 
set of core categories (e.g., specific types of questions, chal-
lenges, and ambiguities concerning social risks). We then 
used codes and subcodes in analysis of all of the inter-
views, with two coders analyzing all interviews. 
Results
Overall, as shown in Table 2 and described more fully 
below, IRBs struggle to define, assess, and balance 
social risks, facing dilemmas—e.g., whether and how 
much to do. In practice, this category often proves 
related to issues of stigma, vulnerability, and social 
inequities that can be ambiguous and difficult to assess. 
Risks to a group can affect individuals within the group, 
and social risks can thus be indirect. These issues posed 
challenges, and none of the interviewees appeared to 
feel that social risks were always easily and readily 
defined, interpreted, and weighed.
Social Risks
In reviewing protocols, many IRBs consider possible 
long-range social risks, such as stigma, but vary in how, 
which, when, and to what degree. IRBs considered 
harms to not solely the individual, but the group (e.g., 
social and psychological harms to a population—
related, for instance, to stigma), and/or social vulnera-
bilities that affect groups as a whole (e.g., related to the 
benefits and burdens of research).
Just because a sample has been de-identified from 
an individual standpoint, doesn’t mean it has been 
from a racial or ethnic group standpoint. There 
could be harm at that level. IRB21 
IRBs may at times consider stigma as a potential long-
range harm. IRBs also recognize that they may differ 
from certain cultural groups in perceiving a study’s 
potential harms. 
This group may have spiritual or worldview-related 
beliefs about that tissue that are much different 
than ours: we want bones of our ancestors returned 
to us, because they’re not merely bones. From their 
perspective, it’s very unpalatable that you have my 
blood or genes in a freezer somewhere and are 
keeping them. So we have to expand our vision. 
IRB21
Questions thus arise as to whether these concerns dif-
fer from the regulations’ dictum not to consider “long-
range” social risks. Data about a vulnerable group may 
be de-identified but, some IRBs fear, still cause social 
harm. Thus, while regulations explicitly state that IRBs 
should specifically not include long-term social harms 
as risks, some IRBs may do so anyway. In part, social 
harms may also harm individuals who are members of 
the affected group. 
These attitudes reflect in part the case of the Havasupai 
Indians, who sued Arizona State University—a case of 
which many interviewees were aware. That well-publicized 
scandal entailed social harm to the tribe: researchers pub-
lished papers based on DNA samples collected that chal-
lenged the group’s beliefs about where they came from. 
The investigators also reported the presence of certain 
stigmatized conditions among the tribe without clearly 
informing the participants that the data would be analyzed 
for these purposes (Mello & Wolf, 2010). The case, which 
was settled out of court, hinged on several issues, includ-
ing inadequate informed consent. Hence, due to concerns 
and fears about perceptions of potential legal liability, IRBs 
may not follow this provision of the regulations to not 
consider “long-term” social risks.
Table 2. Dilemmas IRBs Face Concerning Social Risks
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Questions arise here of whether increased stigma to a 
group, particularly a vulnerable group, in fact constitutes 
long-range social harm. At times, IRBs felt that it did, 
but questions then also arose of how to define “long-
range.” The regulations do not attempt to define it, and 
it is unclear whether it means simply extending beyond 
the point at which the protocol itself ends—e.g., grant 
funding has ended—as opposed to short-term (i.e., in 
the immediate period during which subjects participate 
in the protocol). 
Harms to Vulnerable Groups as Long-Range Social Risks?
Relatedly, IRBs often considered risks to vulnerable 
groups, and wrestled with dilemmas in defining and 
weighing risks to a population. IRBs tried to protect 
against vulnerability, but still often “worry” how effec-
tive safeguards for vulnerable groups are, and should 
be. Uncertainties lingered. One social scientist and for-
mer chair, as a researcher himself, felt it was important 
that science proceed, but other IRBs may be more 
cautious.
We have to weigh the vulnerability of the subjects 
against the pursuit of knowledge—involving HIV, 
drugs, suicide. We try to build the safeguards, but 
know that something can go wrong. IRB22
Removed from the field, IRBs often find such potential 
dangers hard to assess—whether these will occur, and if 
so, which, to what degree, and with what effects, and how 
to weigh these against potential benefits. Balancing pos-
sible harms to vulnerable groups against possible scien-
tific benefits can thus be difficult. 
IRBs also face questions concerning whether and to 
what degree to consider wider health disparities related 
to social risks—e.g., whether to consider possible 
increases in long-range social inequities as a social risk. 
Deciding how and to what degree to incorporate and 
weigh justice concerns—how far and in what ways to 
seek a fair distribution of benefits and burdens of 
research—can be difficult. IRBs generally seek to distrib-
ute the social burdens of research among population 
groups to avoid overly burdening or benefiting any one 
group; but how and to what degree exactly to do so, given 
prior inequities, is often unclear. These issues surface 
with regard to vulnerable populations—e.g., those of 
lower socioeconomic status.
The regulations themselves do not directly address 
these questions. Generally, interviewees felt that in the 
end, IRBs could simply not resolve the larger inequities 
of the health care system in the United States and the 
developing world—that larger health policy issues lay 
beyond the IRB’s scope—but that IRBs nevertheless had 
to take into account the contexts of existing inequalities, 
in which studies were often conducted. For example, 
protocols may propose to exclude patients without insur-
ance, and IRBs then face questions of whether, as a result, 
to disapprove or modify such a study. As one researcher 
and chair said:
The company will provide the drugs for free, but 
bill the insurance company for all the doctor’s visits, 
the time in the hospital, the CT scans, and tests…
[But] what about poor people who don’t have insur-
ance? Here’s a potential life-saving treatment that 
only the rich can get. The drug companies claim 
that they can’t otherwise afford to conduct these 
studies. But many of our IRB members, especially 
our lay members, get upset about this. IRB12
Medicaid and Medicare may cover such treatments, 
but many patients may still not have any insurance or 
resources to cover these expenses. IRB members’ opin-
ions about these issues may also thus differ based on 
their backgrounds and positions on the IRB.
IRB Responses and Solutions
IRBs seek to address these ambiguities and tensions in 
various ways, at times seeking compromises. IRBs con-
front these questions in deciding, for instance, whether 
and how to change a study that may exclude or unfairly 
burden a disadvantaged population. For example, in a 
study that required subjects to have a high-speed 
Internet connection, one IRB developed informal 
“rules,” permitting exclusion of subjects for a pilot 
study, but not for a full protocol:
We decided our rule of thumb is: it’s OK to exclude 
people for a six-month preliminary study. But for a 
Phase II program, a PI needs to get high-speed 
Internet to the participants—have subjects use the 
Internet at a clinic, or pay for it for them for two 
months. IRB26
These compromises can seek middle ground—not fol-
lowing the regulations only in one strictly interpreted 
way. Yet objections can arise, based on other interpreta-
tions of regulations. The interviewee above continued,
A grant reviewer said, “You’re still excluding a 
whole population of people!” The PI answered: 
“We’re not going to be marketing this intervention 
to people who don’t have the technology to support 
it. So it doesn’t matter.” But to exclude people flies 
in the face of justice! IRB26
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IRBs thus wrestle with whether to make exceptions, 
and approve studies that may perpetrate or widen social 
disparities—i.e., whether to see such problems as poten-
tial social risks of a study.
IRBs may allow inequalities to persist and possibly 
increase because doing otherwise would significantly 
burden researchers; but these committees then have to 
decide when and to what degree to do so (given resulting 
costs to researchers). For instance, tensions arise con-
cerning how ethnically diverse an IRB should require a 
sample of subjects to be in a predominantly Caucasian 
region. Many IRBs will want to see a plan for minority 
recruitment. If the population near an institution is 98% 
Caucasian, an IRB could encourage collaboration with 
other regions. But doing so can impose costs that IRBs 
may recognize or weigh differently. IRBs could poten-
tially suggest that PIs collaborate with other institutions, 
because of either the rarity of a disease  or the lack of 
diversity, but such input may not be common. As one 
rural physician and chair said:
Someone could say: why don’t the researchers col-
laborate with researchers in big cities? But there 
would have to be a scientific basis for that. 
Occasionally, though, if the PI is trying to study 
some rare cancer, the committee says, “The tumor 
registry here sees one case per year. You need to 
find collaborators elsewhere.” But it’s usually due to 
rarity, not diversity. IRB14
IRBs may thus overlook justice concerns about sam-
pling, because of both the costs to researchers and the 
lack of clarity in the regulations as to how much IRBs 
should ensure justice versus accept inequities.
Conclusions
In reviewing protocols, IRBs thus struggle with a series 
of dilemmas relating to social risks, and are at times 
unclear how to do so. Committees wrestle with whether, 
when, how, and to what degree to consider social risks, 
related at times to potential increases in stigma, vulner-
ability, and health inequities. For committees, social 
risks frequently prove to be closely related to broader 
issues of justice and injustice. IRBs often see social 
harm as exacerbating social vulnerability and vice 
versa. IRBs thus face underlying tensions concerning 
how to define, interpret, apply, assess, and weigh these 
concerns and certain terms in the federal regulations 
(e.g., “long-range,” “effects,” “social,” “risks,” “fair distri-
bution,” and “vulnerability”). Committees confront 
these issues in the contexts of specific protocols—
whether IRBs, researchers, and funders should be 
responsible concerning social risks, and if so, to what 
degree, and how, and to what degree to seek fair distri-
bution of benefits and burdens.
IRBs encounter difficulties knowing how to assess and 
weigh these issues, which generally cannot be readily 
quantified, and may be much harder to measure than 
individual risks and benefits (which often can be quan-
tified—e.g., a particular drug may have a 25% likelihood 
of eliminating a particular symptom, or causing a par-
ticular side effect). 
In response to ANPRM’s questions about how IRBs 
interpret language about long-range social risks, these 
data suggest that, at times, committees do take these risks 
into account because of concerns about long-term stigma, 
vulnerability, unfair distribution of burdens and benefits 
of research, and legal liability; but that IRBs wrestle with 
when, how, and to what degree to do so. In part, the regu-
lations themselves are unclear—for instance, how long or 
short is “long-range,” and whether “long-range effects” 
refers to effects only on policy, or also on social practices 
and attitudes, including stigma. OHRP, as it is concerned 
about these questions (as reflected in the  ANPRM), 
should thus clarify the intent of the regulations, in order 
to understand how IRBs do and should understand and 
use these terms. Presumably, the regulations’ intent is that 
social risks should not stand in the way of science; but 
IRBs are mandated to uphold nonscientific concerns as 
well (e.g., related to stigma and vulnerability). 
Conceptually, on a theoretical level, philosophers and 
policymakers may see “long-range effects” and “social 
risks” as well-defined, readily demarcated categories. Yet 
in practice, these terms become closely interconnected to 
other social concerns—e.g., heightened stigma, vulnera-
bility, and social inequity. 
Long-range social risks can include and/or blur into 
larger questions of vulnerabilities of populations that 
over time can heighten social inequities. Concerns about 
the vulnerabilities of populations and inequities can thus 
prompt IRBs to consider long-term effects of research 
(e.g., on the perceptions of a group by itself or others). 
Consequently, IRBs, though mandated by the regulations 
to ignore social risks, may nevertheless consider these 
harms, in part because the scope of the terms of the 
regulations is not defined or demarcated. Many inter-
viewees were also well aware of the lawsuit involving the 
Havasupai tribe, and institutions and IRBs may thus be 
concerned, too, about the reputational risks of a scandal 
(i.e., rather than social risks alone, in and of themselves). 
The boundaries between social vs. individual risks can 
also be murky. Increased stigma faced by a population 
can potentially increase the stigma faced by each indi-
vidual within the group. Moreover, the potential future 
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social effects of research (e.g., on policy) can also not be 
easily predicted. Research often has little impact on pub-
lic policy, even when researchers wish their work to have 
more of an effect. Whether a protocol will in fact affect 
policy, and if so, how, and to what degree is thus unclear 
(Sumner et al., 2011). 
These uncertainties are important as they can poten-
tially contribute to variations between IRBs that can 
impede multi-site and other research. The lack of con-
sistency and clearly followed algorithms or approaches 
between IRBs can impact single-site studies, too. An IRB 
may approach a study in an idiosyncratic way that is not 
fully justified, may stymie researchers, and may reflect 
neither the regulation’s intent nor the standards used by 
other IRBs. 
Best Practices
These data have several key implications for best prac-
tices and policy. IRB members are often “removed from 
the field,” and arguably may not always be best suited to 
advise on social risks to a population. IRBs generally try 
to consult with individuals who have expertise about 
other cultural groups that are participating in research. 
Yet these committees often face challenges in obtaining 
such unbiased expertise (i.e., the researcher submitting 
a protocol may know about a local population, but be 
conflicted in assessing the ethics of his or her own pro-
tocol). These data thus suggest the need for further 
sensitivity to, and awareness of, these ambiguities and 
complexities involved in issues related to social risk 
among IRBs, policymakers, and researchers. Clarification 
and guidance from scholars as well as OHRP and/or 
other entities (e.g., Public Responsibility in Medicine 
and Research [PRIM&R], Secretary’s Advisory 
Committee on Human Research Protections [SACHRP], 
or the Institute of Medicine), concerning how IRBs 
should and do define, interpret, assess, and weigh these 
categories (i.e., social risks) could be highly beneficial. 
These data also suggest the need to collect, share, and 
explore “rules of thumb”—ways of handling these ten-
sions—that individual IRBs may have developed, and 
that may help other institutions as well.
Research Agenda
These data also have several important implications for 
future research and scholarship—underscoring needs 
to explore further the definitional and conceptual 
ambiguities highlighted here—e.g., examining, among 
larger samples, how often, when, to what degrees, and 
in what ways IRBs consider and weigh long-term social 
risks, and differ in doing so, and how exactly these con-
siderations affect IRB decisions. Interviewees did not 
mention the lack of reliable evidence to drive decisions, 
whether clinical or not, as a social harm; but it may also 
pose challenges in addressing these issues. 
Educational Implications
These data suggest the possibility that IRB chairs, 
members, staff, policy makers, and researchers may 
benefit from educational efforts targeted at addressing 
these realms, including the complexities and ambigui-
ties involved in definitions and applications of these 
terms, to increase awareness and sensitivity about 
these issues.
These data have several potential limitations. The 
study included interviews with IRB chairs and members, 
not observations of IRB meetings, or written IRB records. 
But future studies can use these other approaches as well. 
These IRB personnel were primarily Caucasian, as has 
been found in other studies of IRBs (Hayes, G. J., Hayes, 
S. C., & Dystra, 1995). Yet the present data did not sug-
gest that, overall, IRB personnel vary significantly based 
on their ethnicity and race in their concerns about social 
risks. Several Caucasian IRB personnel were very dedi-
cated to the treatment and welfare of disadvantaged 
groups and highly concerned about social risks. 
Nonetheless, future research can investigate more fully 
among larger samples whether IRB personnel’s concerns 
do vary based on their race and ethnicity. This research 
may be difficult to conduct, however, since IRB person-
nel are overwhelmingly Caucasian (Hayes, G. J., Hayes, 
S. C., & Dystra, 1995; Campbell et al., 2003). These IRBs 
also reported difficulty recruiting and maintaining 
diverse community members (Klitzman, 2011c). Such 
additional data also may be hard to gather since, anec-
dotally, IRBs have generally required researchers to get 
consent from all IRB members, and relevant PIs and 
funders. This study is based on qualitative data, and thus 
is not designed to quantify responses. Qualitative data is 
valuable in suggesting research questions and hypothe-
ses, and illuminating key social phenomena, meanings, 
and practices. Future studies can quantify frequencies of 
these various phenomena among larger samples, and 
explore statistical associations with other variables. 
In sum, these data—the first to examine how IRBs 
view and make decisions about social risks in protocols 
they have reviewed—highlight how IRBs at times in fact 
consider these issues, but face a range of challenges, 
dilemmas, and ambiguities, and can vary as a result. 
These phenomena have important implications for 
future practice, research, policy, and education.
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Appendix A: Sample Questions from  
Semi-Structured Interview*
•	 Do you think IRBs differ in their views or approach-
es toward research integrity (RI), and if so, when, 
how, and why? What issues about RI has your IRB 
confronted? Which, if any, have been difficult? Why? 
What happened? What other disagreements have 
occurred on your IRB?
•	 Has your IRB confronted issues in assessing social 
risks and benefits, and if so, how, when, and why? 
What issues arose, and how did you address these? 
Was there disagreement on your IRB about these 
issues, and if so, what? How was it resolved?
•	 Should other regulations or guidelines concerning 
IRB reviews of RI or other areas be developed, and if 
so, what?
•	 Do you have any other thoughts about these issues?
* Additional follow-up questions were asked, as appropri-
ate, with each participant.
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